Venetoclax: Martinelli, ‘Farmaco innovativo che induce a morte cellule leucemiche’
(Adnkronos) - “Il Venetoclax è il primo farmaco innovativo, riconosciuto da AIFA, che induce la morte cellulare specifica delle cellule leucemiche, risparmiando quelle sane del sistema immunitario. Lo stiamo portando a valorizzazione in tutta l’Italia”. Così il Direttore Scientifico dell’Istituto Romagnolo per lo Studio dei Tumori ‘Dino Amadori’, Giovanni Martinelli, a margine della conferenza stampa tenutasi all’Hotel Nazionale sulla leucemia mieloide acuta.
Category
🗞
NewsTranscript
00:00 Venetoclax is the first innovative drug,
00:03 recognized by the National Health Service
00:05 by the EFN in recent days,
00:08 that specifically and selectively treats
00:11 acute myeloid leukemia in elderly people
00:14 and in the frail, unfit for conventional chemotherapy.
00:19 It is the first senolytic drug.
00:20 What does it mean?
00:21 It is a drug that induces a specific cellular death
00:24 if you remove the leukemic cells
00:26 and somehow saves normal, healthy cells
00:30 from the immune system of our body and blood.
00:34 So it is a drug that induces immediate healing
00:36 in most patients in a very short time.
00:39 But this is a drug that we started to develop
00:41 several years ago, in 2012.
00:43 We carried out the first experiments
00:44 at the University of Bologna
00:46 and then now at the Institute of Recovery
00:47 and Scientific Cure of Romania.
00:49 And we have seen more than a thousand patients in the world
00:53 treated with this drug,
00:55 which has led, especially elderly patients
00:57 with acute myeloid leukemia,
00:58 to the worst of acute leukemias,
01:02 fragile, unable to undergo chemotherapy,
01:04 to obtain, through this exposure to this drug
01:07 for 21 days,
01:09 to obtain a complete remission of the disease.
01:12 The drug has been registered for 28 days,
01:14 the dosage is a standard dosage.
01:16 Most of our patients
01:18 already get their first cycle of healing,
01:20 which means getting out of the dependency transfusion,
01:22 getting out of the hemorrhagic risk,
01:24 getting out of the infectious risk,
01:27 so patients who do not have pneumonia,
01:28 who do not have serious infections,
01:30 and who completely recover their fitness
01:32 and also the ability to stay with their family.
01:34 It is a great drug that we are finally bringing
01:37 to the value of all of Italy,
01:38 and now all of Italy can use it,
01:40 not only in controlled clinical studies,
01:42 but in an extensive way.